Mumbai: GlaxoSmithKline Pharmaceuticals Limited has announced the appointment of Chinmay Sharma, Executive Vice President - ...

Take a closer look at London's biotech hub – renowned for its thriving life sciences ecosystem and world-class infrastructure ...

London: GSK plc has announced the New Drug Application (NDA) for linerixibat, an investigational targeted inhibitor of the ...

Drugmaker GSK revealed on Monday that a new drug application for its linerixibat asset had been accepted for review by the US ...

(Alliance News) - GSK PLC on Monday announced the US Food & Drug Administration has accepted for review the new drug application for its liver disease treatment, linerixibat.

"Complicated UTIs can have a profound impact on patients and carry a high risk of clinical complications, including sepsis and septic shock," said GSK Chief Scientific Officer Tony Wood. "These ...

There’s already overlap in the pharmaceutical industry between the U.K. and Pennsylvania, but details in Trump’s trade deal ...

This week saw two major life sciences investments in London, as GSK unveiled plans to move its headquarters to a central location in the city, while an ambitious plan to develop a new biosciences ...

GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion).

More about GlaxoSmithKline GlaxoSmithKline (GSK) is a global healthcare company headquartered in London, specializing in pharmaceuticals, vaccines, and consumer healthcare products. The company ...

London-based GSK paid iTeos $625 million upfront for rights to belrestotug four years ago. At the time, interest in TIGIT was riding high as Bristol Myers Squibb, Gilead Sciences, Merck & Co. and ...

You can reach Andrew on Signal at drewqjoseph.45. LONDON — GSK said Wednesday it would purchase an experimental liver disease medicine from Boston Pharmaceuticals for $1.2 billion upfront ...